Patents by Inventor Clarence Eugene Hull

Clarence Eugene Hull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase
    Patent number: 9388181
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 9365575
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 14, 2016
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Kinase inhibitors
    Patent number: 9321766
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: April 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull, III, Thomas C. Malone
  • PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
    Publication number: 20160102088
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 14, 2016
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
  • KINASE INHIBITORS
    Publication number: 20160096832
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 7, 2016
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull III, Thomas C. Malone
  • SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS
    Publication number: 20160096837
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
    Patent number: 9296747
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
  • Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
    Patent number: 9255096
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: February 9, 2016
    Assignee: Allergan, Inc.
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • KINASE INHIBITORS
    Publication number: 20130310394
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 21, 2013
    Applicant: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Kinase inhibitors for the treatment of disease
    Patent number: 7531665
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: May 12, 2009
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20090099181
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: November 16, 2007
    Publication date: April 16, 2009
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Kinase inhibitors for the treatment of disease
    Publication number: 20040198802
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 20, 2004
    Publication date: October 7, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull
  • Kinase inhibitors for the treatment of disease
    Patent number: 6747025
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20040102509
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 13, 2003
    Publication date: May 27, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull